A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RTA 1701 in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2018
At a glance
- Drugs RTA 1701 (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Adverse reactions; First in man
- Sponsors Reata Pharmaceuticals
- 20 Jun 2018 According to a Reata Pharmaceuticals media release, initial results are expected in the first half of 2019.
- 20 Jun 2018 Status changed from planning to recruiting, according to a Reata Pharmaceuticals media release.
- 09 Apr 2018 New trial record